美股市場個股詳情
NUVL Nuvalent
- 66.860
- +0.790+1.20%
收盤價 04/26 16:00 (美東)
- 65.220
- -1.640-2.45%
盤後 19:16 (美東)
43.15億總市值-30811市盈率TTM
66.895最高價65.080最低價23.03萬股成交量66.230今開66.070昨收1532.60萬成交額0.69%換手率虧損市盈率(靜)6454.22萬總股本89.39052周最高6.16市淨率22.28億流通值35.29052周最低--股息TTM3332.26萬流通股89.390歷史最高--股息率TTM2.75%振幅7.090歷史最低66.559平均價1股每手
關於Nuvalent公司
Nuvalent, Inc.是一家臨牀階段的生物製藥公司，專注於爲癌症患者創造精確靶向治療。其產品線包括ROS1 NSCLC、ALK NSCLC和HER2 NSCLC。
公司介紹
公司代碼NUVL
公司名稱Nuvalent
上市日期2021/07/29
發行價格17.00
成立日期2017
CEODr. James R. Porter, PhD
所屬市場納斯達克
員工數量92
證券類型海外普通股
年結日12-31
公司地址One Broadway,14th floor
城市Cambridge
省份麻塞諸塞州
國家美國
郵編02142
電話1-857-357-7000
董事高管
- 姓名
- 職務
- 年薪
- Dr. Matthew Shair, PhD
- Director and Scientific Founder
- 36.04萬
- Dr. James R. Porter, PhD
- Director, Chief Executive Officer and President
- 521.46萬
- Dr. Deborah Miller, J.D.,PhD
- Chief Legal Officer and Secretary
- --
- Alexandra Balcom, M.B.A.
- Chief Financial Officer, Principal Accounting Officer and Treasurer
- 201.98萬
- Dr. Christopher D. Turner, M.D.
- Chief Medical Officer
- 207.98萬
- Darlene Noci, A.C.I.S.
- Chief Development Officer
- --
- Dr. Sapna Srivastava, PhD
- Independent Director
- 17.19萬
- Dr. Andrew A. F. Hack, M.D.,PhD
- Independent Director
- 17.13萬
- Dr. Michael L. Meyers, M.D.,PhD
- Independent Director
- 36.68萬
- Dr. Joseph Pearlberg, M.D.,PhD
- Independent Director
- 16.84萬
- Dr. Emily Drabant Conley, PhD
- Independent Director
- 52.40萬
- Anna Protopapas
- Independent Director
- 55.37萬
- Dr. Cameron Wheeler, PhD
- Independent Director
- 18.17萬
- Dr. D. Gary Gilliland, M.D.,PhD
- Independent Director
- 17.42萬
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
漲跌幅